Teneligliptin Hydrobromide Hydrate/Metformin Hydrochloride

氢溴酸特力利汀/盐酸二甲双胍

Report date: 2022/01/14 13:23:58

Base Information

Drug NameTeneligliptin Hydrobromide Hydrate/Metformin Hydrochloride
Drug Alias NameMetformin/Teneligliptin氢溴酸特力利汀•盐酸二甲双胍盐酸二甲双胍/氢溴酸特力利汀Teneligliptin Hydrobromide/Metformin HydrochlorideTeneligliptin Hydrobromide and Metformin Hydrochloride +[9] 
ClassificationSmall molecules
Mechanisms of ActionProtein kinase AMP-activated non-catalytic subunit beta 1 activatorsDipeptidyl peptidase IV inhibitors
TargetsDipeptidyl peptidase IVProtein kinase AMP-activated non-catalytic subunit beta 1
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaN/A
Original Approved Country/TerritorySouth Korea
Original Approved Date2015/11/03
Country/TerritorySouth Korea
CombinationsYes Teneligliptin Hydrobromide HydrateMetformin Hydrochloride
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesHandok Inc
China Registration ClassN/A

Develop Information

Active CompaniesHandok Inc
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeA10BD
Related LinksN/A